Kuhlman et al. achieved sustained remission in a patient with primary de novo peritoneal MS with CBF rearrangement using 7 + 3 induction therapy followed by gemtuzumab ozogamicin and high-dose cytarabine [6]. The gene discussed is CEBPZ; the disease is myeloid sarcoma.